Imipenem/Cilastatin/Relebactam Alone and in Combination against<i>Pseudomonas aeruginosa</i>in the<i>In Vitro</i>Pharmacodynamic Model
Iris H. Chen, David P. Nicolau, Joseph L. Kuti
Abstract
Combination therapy may enhance imipenem/cilastatin/relebactam’s (I/R) activity against Pseudomonas aeruginosa and suppress resistance development. Human-simulated unbound plasma concentrations of I/R at 1.25 g every 6 h (h), colistin at 360 mg daily, and amikacin at 25 mg/kg daily were reproduced alone and in combination against six imipenem-nonsusceptible P. aeruginosa isolates in an in vitro pharmacodynamic model over 24 h.
Topics & Concepts
Pseudomonas aeruginosaImipenem/cilastatinImipenemColistinAmikacinCilastatinPharmacodynamicsIn vitroPharmacologyMicrobiologyMedicinePharmacokineticsChemistryBiologyAntibioticsBacteriaBiochemistryGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumonia and Respiratory Infections